• Developing cutting edge methods for quantitative pharmacology (High Content Screening, Pharmacokinetics)
• Designing the next generation of anti-TB antibiotics : ethionamide boosters.
• Deciphering the role(s) of Insulin Degrading Enzyme in diabetes with several families of modulators.
• Modulating the molecular interplay between intestine, liver and muscles with TGR5 ligands to treat diabetes.
• Developing small chemical modulators of antigenic presentation.

We are open to any type of collaboration with biologists or chemist from academia and industry where medicinal chemistry, in vitro pharmacology and pharmacokinetics enable or accelerate the translation of new therapeutic concept into drug discovery.

Our researchers are committed to the highest standards of scientific quality and integrity in everything they do. We use up-to date electronic lab books to sustainably capitalize knowledge and facilitate collaborations between multiple research sites.

Most of our researchers are also faculty members who teach in PharmD and MSc courses in pharmacy, drug discovery, medicinal chemistry, organic chemistry, and R&D strategies.

Blondiaux, N., et al. Reversion of antibiotic resistance in M. tuberculosis by SMARt-420. Science,2017, 355(6330): 1206-1211. doi:10.1126/science.aag1006

• Science Mag : Biological version of malware reverses antibiotic resistance in TB
• Nat. Chem. Biol :Out-SMARting drug resistance
• Nat. Rev. Drug Disc. : Reversing resistance
• NEJM : Reviving a Drug for Tuberculosis?
• Le Monde : Tuberculose multirésistante : un vieil antibiotique ressuscité
• C&EN : Reversing resistance to a tuberculosis antibiotic